Glaucoma is a group of disorders associated with retinal ganglion cell (RGC) degeneration and death. There is a clear contribution of mitochondrial dysfunction and oxidative stress toward glaucomatous RGC death. Mitochondrial uncoupling protein 2 (Ucp2) is a wellknown regulator of oxidative stress that increases cell survival in acute models of oxidative damage. The impact of Ucp2 on cell survival during sub-acute and chronic neurodegenerative conditions however is not yet clear. Herein, we test the hypothesis that increased Ucp2 expression will improve retinal ganglion cell survival in a mouse model of glaucoma. We show that increasing retinal ganglion cell but not glial Ucp2 expression in transgenic animals decreases glaucomatous RGC death, but also that the PPAR-γ agonist rosiglitazone, an endogenous transcriptional activator of Ucp2, does not significantly alter RGC loss during glaucoma. Together, these data support a model whereby increased Ucp2 expression mediates neuroprotection during a long-term oxidative stressor, but that transcriptional activation alone is insufficient to elicit a neuroprotective effect, motivating further research in to the posttranscriptional regulation of Ucp2.
Introduction
Hamilton syringe (Hamilton Company Reno, NV, USA). As an internal control, 4 µL of sterile 1x phosphate buffered saline (PBS) was injected in to the contralateral eye. We measured postoperative IOP every 3 days for 30 days. Following terminal IOP measurements, mice were asphyxiated using a Euthanex SmartBox system, which automatically controls CO 2 dispersion, followed by cervical dislocation.
IOP Measurement
Intra-ocular pressure (IOP) was measured in mice anesthetized by 1.5% isoflurane in air (v/v) using an Icare® TonoLab (Icare Finland Oy, Espoo, Finland) rebound tonometer, both before and after injection with polystyrene microbeads. Each reported measurement is the average of 18 technical replicates/mouse/eye. Mice were included in this study if their individual IOP was elevated by ≥3 mmHg or if a paired t-test of IOP over time between microbead and PBS-injected eyes was statistically significant (p<0.05). Baseline and bead-injected IOPs were compared between mouse strains to confirm the absence of any genotype-dependent differences in IOP increase.
Histology and Immunocytochemistry
Immunolabeling of sectioned retinal tissue was performed as previously described (Pinzon-Guzman et al., 2011) . Briefly, whole eyes were fixed in 4% paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA, USA) in 1x PBS overnight at 4°C. The next day, eyes were divided in half with a scalpel blade. One half was frozen and sectioned, while the other was labeled as a whole-mount. Frozen tissues were embedded in a 2:1 mixture of 20% sucrose and OCT (Electron Microscopy Sciences), cooled to -20°C, and cut at a 10 µm thickness. Samples for each experiment were located on the same slide to control for assay variability. Prior to immunohistochemical labeling, we unmasked antigens in a pH 6.0 sodium citrate buffer. Subsequent labeling of oxidative protein carbonyls was performed using an OxyIHC kit (EMD-Millipore, Cat#: S7450). Derivatization of protein carbonyl groups and all subsequent steps were performed in accordance with the manufacturers instructions. Staining intensity was derived using the H-DAB vector of the ImageJ Color Deconvolution tool background was subtracted from each image, resulting in a numerical semiquantitative measure of oxidative tissue stress. Tissue was imaged using an Olympus BX50 microscope. In this and all other experiments, the acquisition parameters for any given label were held constant.
Post-fixation, retinal whole mounts were permeabilized with 0.2% Triton-X-100 in PBS, blocked with 5% nonfat milk, and incubated in rabbit anti-RBPMS antibody (EMD Millipore) for 6 days at 4°C. Tissue was incubated in secondary antibody and 1 µg/mL Hochest-33258 overnight at 4°C prion to washing and mounting with 0.5% n-propyl gallate in 1:1 glycerol: PBS. Whole-mount tissue was imaged on a Fluoview FV1000 confocal microscope (Olympus).
Retinal Ganglion Cell Counting
RGCs were counted in retinal whole-mounts using the marker RBPMS (Rodriguez et al., 2014) across 3-4 317.95 µm x 317.95 µm fields, with each field centered 1000 µm from the optic nerve head. Cell counts were converted to measurements of RGC density, averaged for a single retina, and RGC loss was calculated as the difference in mean RGC density between PBSinjected and contralateral bead-injected retinas. The counter was blinded to the identity of each sample. We did not find a significant effect of retinal quadrant on RGC density normally or with elevated IOP, and our images were therefore taken across all retinal quadrants. The mean±SEM and median RBPMS + RGC densities in PBS-injected retinas (pooled from wild-type C57BL6/J and Ucp2 KI controls) were 4758±113 and 4738 cells/mm 2 , respectively. The mean±SEM and median RBPMS + RGC densities in Bead-injected retinas were 3957±152 and 3858 cells/mm 2 , respectively, leading to an average 17% cell loss 30 days following bead injection.
RNA Isolation and Quantitative Real-Time PCR
Flash frozen cells or tissue were lysed in TRIzol (Thermo-Fischer, Cat#:15596018) and RNA precipitated using the manufacturer's recommended procedure. Final RNA concentration was measured using a NanoDrop ND-1000 Spectrophotometer prior to reverse transcription. We reverse transcribed 300-1000 µg RNA using SuperScript III (Thermo-Fischer, Cat#: 18080093) with random hexamers. cDNA was amplified with iQ SYBR Green Supermix (Bio-Rad, Cat#: 1708882) and amplified on a Bio-Rad iCycler. Ucp2 primer sequences were F: 5'-GCT CAG AGC ATG CAG GCA TCG-3' and R: 5'-CGT GCA ATG GTC TTG TAG GCT TCG -3'. TATA-box binding protein (Tbp) primer sequences were F: 5'-ACC TTA TGC TCA GGG CTT GGC C-3 R: 5'-GTC CTG TGC CGT AAG GCA TCA TTG-3'. Cq's from Ucp2 amplification were normalized against Tbp and controls using the ΔΔC t method.
Primary Astrocyte Culture
Primary mouse cortical astrocytes were isolated from postnatal day 1-4 mice as previously described (Sarafian et al., 2010; Lapp et al., 2014) . Briefly, mice were decapitated and brains were removed from the skull. In tissue culture medium, a ~1 cm portion of superior cerebral cortex was pinched off of the brain using curved forceps. Meninges were removed, and the tissue was triturated with a sterile flame-polished glass Pasteur pipette until it formed a single cell suspension, approximately 20x. The suspension was filtered through a 70 µm cell strainer (Corning, Cat#: 352350) to remove larger debris, centrifuged at 500 x g and 4°C for 5 min, resuspended in growth medium (Dulbecco's Modified Eagle's Medium/Ham's F12 supplemented with 2 mM L-glutamine, 15 mM HEPES, 10% fetal bovine serum, and 10 ng/mL gentamicin), and plated in a T-25 tissue culture flask. Cells were grown at 37°C in a 5% CO 2 /balance air atmosphere. After the cells reached confluence, between 7-14 days in vitro (DIV), contaminating cells were shaken off by rotating at 250 RPM overnight. Astrocyteenriched cultures were plated at 30,000 cells/well on black tissue-culture-treated 96-well plates (Corning, Cat#3603) and used at passage #2 or 3, allowing at least 48 hours following medium replacement before experimentation. All cells used in this study were exposed to 1 µM 4hydroxytamoxifen (Sigma, Cat#: H6278) for 24 hours prior to studies of Ucp2 function.
Measurement of Mitochondrial Membrane Potential and Oxidative Status
We determined mitochondrial membrane potential (Ψ m ) and oxidative status of primary cortical astrocytes using the mitochondrial membrane potential-sensitive dye TMRE (50 nM, ImmunoChemistry, Cat#: 9103) or the mitochondrial superoxide probe MitoSox (5 µM, Thermo-Fischer, Cat#: M36008), which is selectively targeted to mitochondria. Cells were incubated in either dye in prewarmed assay medium (1x PBS supplemented with 1 mM glucose and 2 mM GlutaMax, Thermo-Fischer, Cat#: 35050-061) for 30 min at 37°C, followed by two washes and imaging. MitoSox fluorescence intensity was measured using the kinetic mode of a microplate reader (BioTek Synergy II), which took serial measurements of MitoSox fluorescence over time. The rate of increase in fluorescence (ΔF) over 10 minutes was divided by initial fluorescent intensity (F 0 ) for each well. This rate of increase was normalized to the mean ΔF/F 0 of control 6 cells. We verified the utility of TMRE as an indicator of Ψ m by simultaneously treating cells with the membrane permeant protonophore Carbonyl cyanide-4-(trifluoromethoxy) phenyl-hydrazone (FCCP, 10 µM, Caymen Chemical, Cat#: 15218), which depolarizes Ψ m . Similarly, we used the mitochondrial complex III inhibitor Antimycin A (5 µM) to stimulate ROS production and confirm the utility of MitoSox as an indicator of ROS.
Statistical analysis
Quantified data are represented by that group's mean±sem unless otherwise indicated. We performed all statistical analyses in GraphPad Prism. We determined the statistical effect of one independent variable on 2 groups using a Student's t-test or paired sample t-test in cases where samples were matched (e.g. the control was the contralateral eye of the same animal). We analyzed the effect of one variable on >2 groups using a one-way ANOVA with a Bonferroni post-hoc analysis. We analyzed the effect of 2 variables using a 2-way ANOVA with a Bonferroni's post-hoc analysis. The statistical significance threshold was set at p<0.05 for all tests.
Results

Exogenous Uncoupling Agents Decrease the Generation of Mitochondrial ROS
The positive association between mitochondrial membrane potential (Ψ m ) and the production of reactive oxygen species (ROS) has been well characterized in isolated mitochondria, and we tested the hypothesis that mild mitochondrial uncoupling stimulated by an exogenous protonophore will decrease mitochondrial ROS in intact cells. We treated primary cortical astrocytes with FCCP at a low concentration to uncouple mitochondria without completely dissipating the Ψ m , and found that 10 nM FCCP depolarized the mitochondrial membrane potential (Ψ m ) to 88±4% of control levels, whereas Ψ m was 34±2% of control in astrocytes treated with 10 µM FCCP, a concentration routinely used to maximally depolarize mitochondria (10 µM; Fig. 1A ). 10 nM FCCP added to MitoSox loaded cells did not significantly alter mitochondrial superoxide generation (data not shown), so we tested the hypothesis that uncoupling will reduce ROS production by dysfunctional mitochondria. To test this hypothesis we loaded cells with the mitochondrion-targeted superoxide probe MitoSox and treated them with the mitochondrial complex III inhibitor Antimycin A (AA; 5 µM). AA significantly increased the rate of MitoSox oxidation (p<0.001, Fig. 1B ), but this increase was partially attenuated in cells simultaneously treated with AA and 10 nM FCCP (p<0.05, Fig. 1B) . These data show that uncoupling decreases the generation of ROS by cultured astrocytes with dysfunctional mitochondria.
Uncoupling Protein 2 Decreases Ψ m and ROS Production
To determine whether mitochondrial uncoupling proteins have the same cellular effects as chemical protonophores on Ψ m and ROS production, we isolated cortical astrocytes from Ucp2 KI ; GFAP-creER T2 mice. Ucp2 expression is elevated roughly 3-fold in GFAP-creER T2 expressing cells of these mice following exposure to 4-hydroxytamoxifen ( Fig. 2A) , and we tested the hypothesis that the addition of transgenic Ucp2 will decrease Ψ m and the generation of ROS. Our data show that Ucp2 knock-in depolarizes Ψ m to 72±7% of control levels (p=0.0095, Fig. 2B ), with 10 µM FCCP decreasing TMRE fluorescence to 54±5% of controls (p=0.0002). Increasing Ucp2 levels decreased the production of ROS, monitored by the change in MitoSox 7 fluorescence over time and normalized to the mean fluorescent intensity of Ucp2 KI control samples (p=0.043; Fig. 2C ). Together, these data show that increased Ucp2 expression decreases Ψ m and mitochondrial ROS, which may be similar in mechanism to the protective effects promoted by 10 nM FCCP.
Elevated IOP increases Ucp2 Expression
To determine whether Ucp2 expression is positively or negatively related to the progression of glaucoma, we analyzed publically available data from a microarray (https://www.ncbi.nlm.nih.gov/sites/GDSbrowser?acc=GDS3899) that determined gene expression changes in the retina and optic nerve heads of 10.5 month-old DBA/2J mice and DBA/2J; Gpnmb + controls (Howell et al., 2014) . DBA/2J are genetically predisposed towards glaucoma, and DBA/2J; Gpnmb + controls are genetically identical to these mice, except for in the Gpnmb gene, for which these control mice express a wild-type copy. Relative to the housekeeping gene Tbp, Ucp2 expression is elevated early in glaucoma, but decreases with increasing disease severity (p<0.05, Figure 3A ). We confirmed these data in a microbead model of glaucoma, and found that 3 days following microbead-injection, intra-ocular pressure (IOP) is significantly elevated (p<0.05, Fig. 3B ). Following IOP measurement, we determined Ucp2 expression in the retinas of these mice, and found that Ucp2 expression increases proportionally with IOP (r 2 =0.8, p=0.0001 Fig. 3C ). These data suggest that Ucp2 may play a role in the retinal response to IOP elevation.
Elevated Ucp2 Expression in RGCs but not Astrocytes or Müller Glia is Protective Against Glaucoma
To determine whether the protective effects of Ucp2 expression in cells translate to the same in vivo system, we used mice in which Ucp2 expression can be increased in Gfap-or Thy1expressing cells following exposure to tamoxifen (Fig. 4A) . Following eight consecutive 100 mg/kg/day injections, we found that GFAP-creER T2 expression increased Ucp2 transcript levels to 165±14% of control (p<0.01, n=6), and Thy1-creER T2 increased Ucp2 to 229±77% of Ucp2 KI controls (p<0.05, n=3, Fig. 4B ). Following exposure to tamoxifen, cells express eGFP, pictured in Fig. 4C , though notably, YFP, which spectrally overlaps with eGFP, is expressed both before and after tamoxifen injection in Thy1-creER T2 retinas (Fig. 4C ). The white arrows in Fig. 4C indicate regions of each cre variant that are structurally distinct, including müller glia fibers (top) and retinal ganglion cell soma (bottom).
We injected microbeads or PBS in to the anterior chambers of these mice, elevating IOP by an average of 5.3 mmHg in Ucp2 KI control mice, 2.4 mmHg in Ucp2 KI ; GFAP-creER T2 mice, and 7.5 mmHg in Ucp2 KI ; Thy1-creER T2 mice (Fig. 5A ). Bead injection in control mice caused a significant loss in RGCs (1018±88 cells/mm 2 for a 19±3% reduction in RGCs; n=11) that was attenuated in mice overexpressing Ucp2 in RGCs (Ucp2 KI ; Thy1-creER T2 , 492±175 cells/mm 2 for a 10±4% reduction; n=9), but not in Ucp2 KI ; GFAP-creER T2 mice (824±225 cells/mm 2 for a 15±4% reduction, n=6, Fig. 5C-D) . These data demonstrate that Ucp2 decreases RGC loss due to elevated IOP over a subacute timeframe, and also that the beneficial effects of Ucp2 are cell autonomous, as Ucp2-overexpression in GFAP-positive glia is insufficient to decrease glaucoma-related RGC loss (Fig. 5C ). The protective effects of Ucp2 expression coincided with decreases in oxidative protein carbonylation, measured by OxyIHC labeling. Bead-injected retinas from Ucp2 KI ; Thy1-creER T2 mice (n=4) were labeled 27±6% less strongly than 8 corresponding Ucp2 KI controls (p<0.05, n=7). In contrast, labeling of Ucp2 KI ; GFAP-creER T2 retinas was non-significantly reduced by 11±11% (n=3, Fig. 6A-B ) relative to controls.
Transcriptional Activation of Ucp2 is Insufficient to Decrease Microbead-Induced RGC Loss.
Past literature suggests that Ucp2 transcription is in part regulated by a PGC1-α/PPAR-γ axis (Chen et al., 2006; Donadelli et al., 2014) . Rosiglitazone (RSG) is an FDA-approved PPARγ agonist. We confirmed that retinal Ucp2 expression can increase 24 hours following exposure to 10 mg/kg rosiglitazone (Fig. 7B) , and hypothesized that due to transcriptional activation of Ucp2, dietary rosiglitazone confers the same resistance to damage in glaucoma as transgenic Ucp2 overexpression. To test this hypothesis, we increased IOP in control-and RSG-fed WT mice ( Fig. 7A) and measured RGC loss 30 days following bead injection. The difference in RGC density between the PBS-and bead-injected eyes in WT control mice was 569±170 cells/mm 2 (n=3), compared to 961±210 cells/mm 2 in RSG-fed mice (n=4). The degree of cell loss was generally lower than in Ucp2 KI controls, which can be explained by the more advanced age of these mice (3.8 months), which has been demonstrated to reduce the effectiveness of RGC loss following bead injection (Cone et al., 2010) . Regardless, the result of this pilot study on the effects of RSG ran contrary to our expectations and did not decrease retinal ganglion cell death, and in fact appeared to non-significantly increase RGC loss ( Fig. 7C-D) .
Discussion
Mild, homeostatic levels of ROS are important signals of mitochondrial damage (Frank et al., 2012) among other physiological signals (Angelova and Abramov, 2016) . When ROS production exceeds the capacity for detoxification by antioxidants, they damage cellular components in a variety of pathogenic conditions. In glaucoma, mitochondria are damaged (Abu-Amero et al., 2006) , suggesting that the retina is oxidatively compromised (Feilchenfeld et al., 2008; Chidlow et al., 2017) .
Partial dissipation of mitochondrial Ψ m may decrease the generation of mitochondrial ROS during glaucoma (Fig. 6 ). Using a cell culture system, we found that decreases in Ψ m also decrease ROS production following mitochondrial dysfunction (Fig. 1) , similar to data generated using isolated mitochondria (Korshunov et al., 1997; Miwa et al., 2003) . We also confirmed that as with other studies (Diano et al., 2003; Lapp et al., 2014) , expression of the mitochondrial uncoupling protein Ucp2 is negatively correlated with both Ψ m and mitochondrial ROS (Fig. 2,6 ). Ucp2 expression is altered during different stages of glaucoma, and appears to increase with increasing IOP (Fig. 3) . However, we note that it is likely that during later stages of glaucoma, Ucp2 levels may fall, as we have seen in the data from (Howell et al., 2011) . We believe that the decrease in Ucp2 later in the disease may be a reflection of the decrease in ganglion cell number, which decreases with increased glaucoma severity. If increased ganglion cell Ucp2 expression reflects a physiological response to increased ROS in glaucoma, artificially increasing Ucp2 may increase the ability of that stress response to increase cell survival. We indeed found that following microbead-injection, we see an increase in retinal Ucp2 expression (Fig. 5) . The hypothesis that Ucp2 improves cell survival following a cellular stressor is also strongly supported by previous studies (Diano et al., 2003; Mattiasson et al., 2003; Andrews et al., 2005; Barnstable et al., 2016) , but the novelty of our study is that in rodent models of glaucoma, retinal ganglion cell death is progressive over time (Huang et al., 2018) , suggesting that Ucp2 is not exclusively protective during acutely stressful conditions, but also during chronic 9 neurodegeneration, decreasing the accumulation of oxidative damage (Fig. 6 ) and bead-induced retinal ganglion cell loss.
Ucp2-mediated neuroprotection is dependent on cell type, as we show that increased Ucp2 levels in Gfap-expressing glia does not significantly alter retinal ganglion cell loss or oxidative stress-derive protein carbonyls compared to controls (Fig. 5-6) . A much larger sample size may be sufficient to demonstrate a neuroprotective effect, supported by a trend towards decreased oxidative stress and RGC loss in Ucp2 KI ; GFAP-creER T2 mice, but overall the data argue for much weaker if any Ucp2-mediated neuroprotection from glial cells than from RGCs. This seems to suggest that changes in mitochondrial dynamics within Gfap-expressing glia of the retina may not be central for the progression of glaucoma, which is unexpected given the many changes they undergo over the course of the disease (Woldemussie et al., 2004) and the protection they give to RGCs (Kawasaki et al., 2000) .
Rosiglitazone is a PPAR-γ-dependent transcriptional activator of Ucp2 (Medvedev et al., 2001; Chen et al., 2006) , and increases retinal Ucp2 expression ( Fig. 7) , but does not seem to promote Ucp2 mediated neuroprotection in the microbead model of glaucoma. PPAR-γ appears to be expressed with high specificity in müller glia cells of the rodent retina (Zhu et al., 2013) , and while the failure of rosiglitazone to protect RGCs was initially surprising, it likely increases the transcription of glial Ucp2. Ucp2 overexpression in Gfap-expressing glia failed to protect RGCs, so our experiments using RSG-fed and Ucp2 KI ; GFAP-creER T2 mice largely support each other. PPAR-γ agonism with pioglitazone is sufficient to decrease RGC loss following optic nerve crush in rats (Zhu et al., 2013) or retinal ischemia/reperfusion injury in mice (Zhang et al., 2017) , suggesting that glial Ucp2 expression may be protective against more acute retinal insults. This protection may also result from the increase in neural PPAR-γ following optic nerve crush (Zhu et al., 2013) , which would allow for agonist-stimulated Ucp2 mRNA expression that is likely subject to multiple endogenous regulatory mechanisms (Donadelli et al., 2014) , unlike the Ucp2 derived from our transgenic mice (Toda et al., 2016) . Overall, a larger study of Ucp2 and PPAR-γ in retinal disease that uses multiple models and agonists/antagonists may yield a clearer picture that captures the cell type specific dynamics of these factors, and changes during different paradigms of retinal damage.
Overall, our data suggests that the greatest protection against RGC loss can be provided by stimulating Ucp2 expression in RGCs. Expression of this gene in other cell types may not be harmful, but our results suggest that the choice of therapeutic target should be dictated in part by cell type. The expression and activity of this protein is also tightly regulated, so the future studies on Ucp2-mediated neuroprotection should also focus on the factors that manipulate Ucp2 transcription, translation, and functional activity. 
